Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Non-Current Debt came in at $292.3 million in Q1 2026, up 16.18% year-on-year from $251.6 million in Q1 2025, and down 8.52% quarter-over-quarter from $319.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $292.3 million for Q1 2026.
- On a quarterly basis, Non-Current Debt rose 16.18% year-over-year to $292.3 million in Q1 2026; TTM through Mar 2026 was $292.3 million, a 16.18% increase from a year earlier, with the FY2025 full-year figure at $319.5 million, up 3.73% from the prior year.
- Non-Current Debt retreated to $292.3 million in Q1 2026 per AAWH's latest filing, from $319.5 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $343.7 million in Q3 2025 and bottomed at $222.6 million in Q1 2022.
- The 5-year median for Non-Current Debt is $297.6 million (2023), against an average of $293.3 million.
- Across the five-year window, Non-Current Debt surged 169.31% in 2022 and fell 23.12% in 2024, its largest moves.
- Year by year, Non-Current Debt stood at $319.3 million in 2022, then decreased by 6.81% to $297.6 million in 2023, then rose by 3.51% to $308.0 million in 2024, then gained by 3.73% to $319.5 million in 2025, then dropped by 8.52% to $292.3 million in 2026.
- Per Business Quant, the three latest AAWH Non-Current Debt figures stand at $292.3 million (Q1 2026), $319.5 million (Q4 2025), and $343.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | 292.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 292.31 Mn |
| Dec 31, 2025 | 319.52 Mn |
| Sep 30, 2025 | 343.75 Mn |
| Jun 30, 2025 | 323.44 Mn |
| Mar 31, 2025 | 251.61 Mn |
| Dec 31, 2024 | 308.02 Mn |
| Sep 30, 2024 | 232.16 Mn |
| Jun 30, 2024 | 289.53 Mn |
| Mar 31, 2024 | 288.70 Mn |
| Dec 31, 2023 | 297.57 Mn |
| Sep 30, 2023 | 301.99 Mn |
| Jun 30, 2023 | 300.78 Mn |
| Mar 31, 2023 | 321.42 Mn |
| Dec 31, 2022 | 319.30 Mn |
| Sep 30, 2022 | 290.97 Mn |
| Jun 30, 2022 | 282.05 Mn |
| Mar 31, 2022 | 222.59 Mn |
| Dec 31, 2021 | 230.85 Mn |
| Sep 30, 2021 | 230.50 Mn |
| Jun 30, 2021 | 104.73 Mn |